EyePoint Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Rhea-AI Summary
EyePoint (Nasdaq:EYPT) granted non-statutory stock options as inducement awards to three new employees under NASDAQ Listing Rule 5635(c)(4). The awards cover up to 39,700 shares of common stock, granted June 15, 2026, with a ten-year term and exercise price of 12.08 per share.
Options vest over four years, with 25% after one year and the remainder in equal monthly installments over three years, subject to continued employment.
AI-generated analysis. How Rhea-AI works. Not financial advice.
Positive
- None.
Negative
- None.
News Market Reaction – EYPT
On the day this news was published, EYPT gained 6.62%, reflecting a notable positive market reaction. Argus tracked a peak move of +3.8% during that session. Our momentum scanner triggered 23 alerts that day, indicating elevated trading interest and price volatility. This price movement added approximately $68M to the company's valuation, bringing the market cap to $1.10B at that time.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| May 19 | Investor conferences | Positive | +1.0% | Announced management participation in three upcoming ophthalmology and healthcare conferences. |
| May 18 | Inducement grants | Neutral | -5.3% | Granted stock options to new employees under NASDAQ Rule 5635(c)(4). |
| May 14 | Clinical trial update | Positive | -1.4% | Third positive DSMC recommendation for Phase 3 DURAVYU wet AMD trials to continue unchanged. |
| May 06 | Earnings results | Negative | -2.9% | Reported Q1 2026 results with low revenue, high operating expenses, and a larger net loss. |
| Apr 29 | Earnings date notice | Neutral | -4.5% | Announced timing and webcast details for upcoming Q1 2026 earnings call. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Recent news has often been clinical or corporate, with mixed price reactions; positive clinical updates previously saw modest downside, while routine items like earnings dates also coincided with declines.
Over the last few months, EyePoint has highlighted clinical progress in its Phase 3 DURAVYU program, earnings results, investor conference participation, and prior inducement grants. Notably, the May 14 DSMC recommendation for Phase 3 wet AMD trials and the May 6 Q1 2026 results framed the company as investing heavily ahead of expected topline data. Routine items like earnings dates and conference announcements saw small negative or modest positive moves, suggesting that similar administrative news, such as today’s inducement grants, has not consistently driven strong upside.
Regulatory & Risk Context
Key Terms
non-statutory stock options financial
nasdaq listing rule 5635(c)(4) regulatory
AI-generated analysis. How Rhea-AI works. Not financial advice.
WATERTOWN, Mass., June 16, 2026 (GLOBE NEWSWIRE) -- EyePoint, Inc. (Nasdaq: EYPT), a company committed to developing and commercializing therapeutics to help improve the lives of patients with serious retinal diseases, today announced that the Company granted non-statutory stock options to new employees as inducement awards outside the Company’s 2023 Long-Term Incentive Plan in accordance with NASDAQ Listing Rule 5635(c)(4).
The Company granted stock options to purchase up to an aggregate of 39,700 shares of EyePoint common stock to three new employees. The stock options were granted on June 15, 2026. The grants were approved by the Compensation Committee and made as an inducement material to each employee entering into employment with EyePoint in accordance with NASDAQ Listing Rule 5635(c)(4). The option awards have an exercise price of 12.08 per share, the closing price of EyePoint’s common stock on June 15, 2026. The options have a ten-year term and vest over four years, with
About EyePoint
EyePoint, Inc. (Nasdaq: EYPT) is a clinical-stage biopharmaceutical company committed to developing and commercializing innovative therapeutics to improve the lives of patients with serious retinal diseases. The Company’s lead product candidate, DURAVYU™, is an innovative investigational sustained delivery treatment for serious retinal diseases combining vorolanib, a selective and patent-protected tyrosine kinase inhibitor, in next-generation bioerodible Durasert E™ technology. Supported by robust safety and efficacy data across multiple clinical trials and indications, DURAVYU is currently being evaluated in Phase 3 pivotal trials for wet age-related macular degeneration (wet AMD) and diabetic macular edema (DME). Topline data is expected for wet AMD beginning in mid-2026.
The Company is committed to partnering with the retina community to improve patient lives while creating long-term value, with four approved drugs over three decades and tens of thousands of eyes treated with EyePoint innovation.
EyePoint is headquartered in Watertown, Massachusetts, with a commercial manufacturing facility in Northbridge, Massachusetts.
Vorolanib is licensed to EyePoint exclusively by Equinox Sciences, a Betta Pharmaceuticals affiliate, for the localized treatment of all ophthalmic diseases outside of China, Macao, Hong Kong and Taiwan.
DURAVYU™ has been conditionally accepted by the FDA as the proprietary name for EYP-1901. DURAVYU is an investigational product; it has not been approved by the FDA. FDA approval and the timeline for potential approval is uncertain.
Investors:
Tanner Kaufman / Jenni Lu
FTI Consulting
tanner.kaufman@fticonsulting.com / jenni.lu@fticonsulting.com
Media:
Helen O’Gorman
FTI Consulting
helen.ogorman@fticonsulting.com
